Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297321 | 0.81 | MKNK1 (0.35) | MKNK1MAPK14DYRK1A | |
| SCHEMBL19338489 | 0.74 | MKNK1 (0.38) | MKNK1DYRK1A | |
| SCHEMBL11785295 | 0.69 | MKNK1 (0.38) | MKNK1DYRK1A | |
| SCHEMBL14306269 | 0.69 | MKNK1 (0.38) | MKNK1DYRK1A | |
| SCHEMBL16417549 | 0.69 | SMN1; SMN2 (0.41) | MKNK1CYP1A2DYRK1A | |
| SCHEMBL2764570 | 0.69 | KDM4E (0.50) | MKNK1DYRK1A | |
| SCHEMBL14325766 | 0.69 | MKNK1 (0.38) | MKNK1DYRK1A | |
| SCHEMBL2763216 | 0.69 | MKNK1 (0.38) | MKNK1DYRK1A | |
| SCHEMBL19957717 | 0.69 | MKNK1 (0.42) | MKNK1DYRK1A | |
| SCHEMBL9935156 | 0.69 | MKNK1 (0.38) | MKNK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| WO-2015144804-A1 | COMBINATIONS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-01 | — | — | WO | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | MKNK1 3820/4885MAPK14 3508/4885CYP1A2 713/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | MKNK1 4346/4885MAPK14 4409/4885CYP1A2 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.